Clinical indications for nirsevimab immunoprophylaxis against severe respiratory syncytial virus infections in infants and children <19 months

Population	Indications
Healthy infants	Born during RSV season or <8 months when entering their first RSV season If dose not received during first RSV season and <8 months upon entering their second RSV season
Infants with increased risk of severe disease: Children with chronic lung disease of prematurity^* who required medical support^¶ any time during the 6-month period before the start of the RSV season Children who are severely immunocompromised Children with cystic fibrosis who have manifestations of severe lung disease^Δ or have weight-for-length that is <10^th percentile American Indian and Alaska Native children	All infants born during RSV season or upon entering their first RSV season If <19 months when entering their second RSV season

This table summarizes our suggested indications for nirsevimab. Refer to UpToDate's topic on RSV prevention for additional details, including a description of the evidence supporting the efficacy of nirsevimab. If nirsevimab is not available, refer to UpToDate's topic on RSV prevention for palivizumab indications.

RSV: respiratory syncytial virus.

* Chronic lung disease of prematurity is also known as bronchopulmonary dysplasia.

¶ Examples include chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen.

Δ Previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable.

Graphic 142933 Version 1.0

خرید پکیج

Clinical indications for nirsevimab immunoprophylaxis against severe respiratory syncytial virus infections in infants and children <19 months